Showing 2861-2870 of 5804 results for "".
- FDA Clears Syneron Candela's UltraShape Power for Fat Destructionhttps://practicaldermatology.com/news/fda-clears-syneron-candelas-ultrashape-power-for-fat-destruction/2458499/The FDA cleared Syneron Medical Ltd.'s non-invasive fat destruction device, UltraShape Power. for non-invasive reduction of abdominal circumference via fat cell destruction. UltraShape Power uses focused, pulsed mechanical ultrasound energy to target and destroy fat, offering measurab
- FDA Advisory Committee Votes to Approve Biosimilar Etanercept from Sandozhttps://practicaldermatology.com/news/fda-advisory-committee-votes-to-approve-biosimilar-etanercept-from-sandoz/2458502/The US FDA Arthritis Advisory Committee recommended approval of Sandoz's proposed biosimilar etanercept. The committee voted unanimously (20-0), in support of biosimilar etanercept for all five indications of the reference product, including rheumatoid arthritis (RA), plaque psoriasis (PsO),
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Global Psoriasis Survey: 85% of US Respondents Faced Social Stigma Because of Psoriasishttps://practicaldermatology.com/news/global-psoriasis-survey-85-of-us-respondents-faced-social-stigma-because-of-psoriasis/2458514/Novartis released new results from its Clear About Psoriasis Survey, the largest global survey to date of people with moderate-to-severe psoriasis. Findings reveal 85 percent of US respondents have suffered from social stigma like discrimination and humiliation because of their disease. In additi
- It's Official: Botox Makes Us Feel Better About Ourselveshttps://practicaldermatology.com/news/its-official-botox-makes-us-feel-better-about-ourselves/2458516/Patient satisfaction with overall facial appearance increases by 28 percent with botulinum toxin type A injections to the glabellar rhytids, according to new research in the Aesthetic Surgery Journal. In the study, sati
- New Hair Restoration Group Started for Dermatologists, Facial Plastic Surgeons and Plastic Surgeonshttps://practicaldermatology.com/news/new-hair-restoration-group-started-for-dermatologists-facial-plastic-surgeons-and-plastic-surgeons/2458525/Introducing The North American Society for Hair Restoration (NASHR), a new non-profit medical association comprising plastic surgeons, facial plastic surgeons and dermatologists who have the proper training for hair transplantation surgery.
- Free Sunscreen Program Expands in Massachusetts Thanks to $25,000 Gifthttps://practicaldermatology.com/news/free-sunscreen-program-expands-in-mass-thanks-to-25000-gift/2458526/The Melanoma Foundation of New England (MFNE) received a $25,000 gift from the Arbella Insurance Foundation to allow its Practice Safe Skin program
- The La Roche-Posay North American Foundation Awards 2016 Grant Winnershttps://practicaldermatology.com/news/the-la-roche-posay-north-american-foundation-awards-2016-grant-winners/2458530/Committed to working alongside dermatologists, La Roche-Posay's North American Fondation encourages residents, fellows and practitioners with at least two years beyond training to develop innovative programs. The brand and a board of certified dermatologists awards two to three w
- With $25 Million Financing, Suneva Medical Gets Ready to Up Their Gamehttps://practicaldermatology.com/news/with-25-million-financing-suneva-medical-gets-ready-to-up-their-game/2458531/Suneva Medical closed $25 million financing to support continued growth opportunities, the company reports. This financing, which includes $25 million equity investment from Essex Woodlands, strengthens Suneva Medi
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,